Answers are grounded in this paper and cite their sources.
In this 24-week trial, reduction of neutrophil serine protease activity with brensocatib in patients with bronchiectasis was associated with improvements in bronchiectasis clinical outcomes. (Funded by Insmed; WILLOW ClinicalTrials.gov number, NCT03218917.).
No takes yet. Share an insight, caveat, or question.
Chalmers et al. (2020) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: